These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8606910)

  • 1. Socioeconomic analysis of addictions treatment.
    Langenbucher JW
    Public Health Rep; 1996; 111(2):135-7. PubMed ID: 8606910
    [No Abstract]   [Full Text] [Related]  

  • 2. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does treatment 'pay for itself'? Looking at the economic argument for addiction treatment.
    Ettner SL
    Behav Healthc; 2006 May; 26(5):32-4. PubMed ID: 16736917
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating managed mental health programs.
    Whitted GS; Kunnes R
    AAPPO J; 1993; 3(2):27-30. PubMed ID: 10171662
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving cost-effectiveness in a substance abuse treatment program.
    Francis E; Hughes P; Schinka J
    Psychiatr Serv; 1999 May; 50(5):633-5. PubMed ID: 10332897
    [No Abstract]   [Full Text] [Related]  

  • 7. The effectiveness of drug treatment.
    Gerstein DR
    Res Publ Assoc Res Nerv Ment Dis; 1992; 70():253-82. PubMed ID: 1311121
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financing of substance abuse treatment for children and adolescents. Committee on Child Health Financing and Committee on Substance Abuse, American Academy of Pediatrics.
    Pediatrics; 1995 Feb; 95(2):308-10. PubMed ID: 7838656
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug treatment takes a hit. As substance abuse has surged among teens, coverage for care has been curtailed.
    Gardner J
    Mod Healthc; 1996 Oct; 26(43):66, 68, 70-2. PubMed ID: 10172795
    [No Abstract]   [Full Text] [Related]  

  • 11. Substance abuse treatment: outcomes of managed care techniques.
    Chung R; Filstead WJ
    Behav Healthc Tomorrow; 1995; 4(6):78-9, 58. PubMed ID: 10172617
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in spending for substance abuse treatment, 1986-2003.
    Mark TL; Levit KR; Vandivort-Warren R; Coffey RM; Buck JA;
    Health Aff (Millwood); 2007; 26(4):1118-28. PubMed ID: 17630455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of cost-benefit analysis in integration projects on drug addiction].
    Ates T; Langer B; Erbas B; Tretter F; Wehner B
    Gesundheitswesen; 2005 Feb; 67(2):159-62. PubMed ID: 15747208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance abuse and the Health Security Act: a case study of a benefit under the Clinton health plan.
    Nakken JM; Nelson BH
    J Health Hosp Law; 1994 Feb; 27(2):50-8. PubMed ID: 10171942
    [No Abstract]   [Full Text] [Related]  

  • 16. Michigan's substance abuse services: readiness for managed care.
    Stauffer M
    Behav Healthc Tomorrow; 1995; 4(4):57-8. PubMed ID: 10172404
    [No Abstract]   [Full Text] [Related]  

  • 17. Public substance abuse and managed behavioral healthcare. American Managed Behavioral Healthcare Association and National Association of State Alcohol and Drug Abuse Directors, Inc.
    Behav Healthc Tomorrow; 1999 Feb; 8(1):25-30. PubMed ID: 10346117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response on drug policy.
    McDonough JR
    Public Health Rep; 1999; 114(2):99-100. PubMed ID: 10199704
    [No Abstract]   [Full Text] [Related]  

  • 19. Five-year trajectories of health care utilization and cost in a drug and alcohol treatment sample.
    Parthasarathy S; Weisner CM
    Drug Alcohol Depend; 2005 Nov; 80(2):231-40. PubMed ID: 15916868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data.
    Harwood HJ; Hubbard RL; Collins JJ; Rachal JV
    NIDA Res Monogr; 1988; 86():209-35. PubMed ID: 3140032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.